Answers are grounded in this paper and cite their sources.
Metastatic prostate cancer, which presents as either de novo (4–5% of cases) or as a recurrence following definitive therapy for localized disease, has historically been treated with androgen deprivation therapy (ADT) alone. Although 90% of men initially respond to ADT, almost all eventually become castration-resistant and develop progression of their disease.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: